Table of Contents
ISRN Gastroenterology
Volume 2012, Article ID 902320, 5 pages
http://dx.doi.org/10.5402/2012/902320
Clinical Study

Inappropriate Use of Gastric Acid Suppression Therapy in Hospitalized Patients with Clostridium difficile—Associated Diarrhea: A Ten-Year Retrospective Analysis

1Department of Gastroenterology, Nassau University Medical Center, East Meadow, NY 11554, USA
2Department of Internal Medicine, Nassau University Medical Center, East Meadow, NY 11554, USA

Received 14 March 2012; Accepted 5 April 2012

Academic Editors: C.-Y. Chen and V. Savarino

Copyright © 2012 Sadat Rashid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Aseeri, T. Schroeder, J. Kramer, and R. Zackula, “Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients,” American Journal of Gastroenterology, vol. 103, no. 9, pp. 2308–2313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. J. J. Heidelbaugh and J. M. Inadomi, “Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients,” American Journal of Gastroenterology, vol. 101, no. 10, pp. 2200–2205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Dial, J. A. C. Delaney, V. Schneider, and S. Suissa, “Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy,” Canadian Medical Association Journal, vol. 175, no. 7, pp. 745–748, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. N. Choudhry, H. Soran, and H. M. Ziglam, “Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease,” QJM, vol. 101, no. 6, pp. 445–448, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. T. Vanderhoff and R. M. Tahboub, “Proton pump inhibitors: an update,” American Family Physician, vol. 66, no. 2, pp. 273–280, 2002. View at Google Scholar · View at Scopus
  6. Clostridium difficile-associated diarrhea (CDAD) and proton pump inhibitor therapy: CAG position statement,” Canadian Journal of Gastroenterology, vol. 19, pp. 1–3, 2005.
  7. “ASHP therapeutic guidelines on stress ulcer prophylaxis: ASHP commission on therapeutics and approved by the ASHP Board of Directors on November 14, 1998,” American Journal of Health-System Pharmacy, vol. 56, pp. 347–379, 1999.
  8. Aciphex [package insert]. Eisai Inc. and Janssen Pharmaceuticals Inc., Titusville, NJ, USA, 2008.
  9. Nexium [package insert]. AstraZeneca LP, Wilmington, Del, USA, 2008.
  10. Prevacid [package insert]. TAP Pharmaceuticals Inc., Deerfield, Mich, USA, 2007.
  11. Prilosec [package insert]. AstraZeneca LP, Wayne, Pa, USA, 2008.
  12. Protonix [package insert]. Wyeth Pharmaceuticals, Inc., Philadelphia, Pa, USA, 2007.
  13. Zegerid [package insert]. Santarus, Inc., San Diego, Calif, USA, 2008.
  14. Kapidex [package insert]. Takeda Pharmaceuticals America, Inc., Osaka, Japan, 2009.
  15. B. R. Dalton, T. Lye-Maccannell, E. A. Henderson, D. R. MacCannell, and T. J. Louie, “Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting,” Alimentary Pharmacology and Therapeutics, vol. 29, no. 6, pp. 626–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Howell, V. Novack, P. Grgurich et al., “Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection,” Archives of Internal Medicine, vol. 170, no. 9, pp. 784–790, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Linsky, K. Gupta, E. V. Lawler, J. R. Fonda, and J. A. Hermos, “Proton pump inhibitors and risk for recurrent Clostridium difficile infection,” Archives of Internal Medicine, vol. 170, no. 9, pp. 772–778, 2010, Erratum in Archives of Internal Medicine, vol. 170, no. 13, pp. 1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Dial, J. A. C. Delaney, A. N. Barkun, and S. Suissa, “Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease,” Journal of the American Medical Association, vol. 294, no. 23, pp. 2989–2995, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Dial, K. Alrasadi, C. Manoukin, A. Huang, and D. Menzies, “Risk of Clostridium difficile diaarhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies,” Canadian Medical Association Journal, vol. 171, no. 1, pp. 33–38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. R. Gingold, G. Narasimhan, S. Augello, and D. J. Clain, “The prevalence of proton pump inhibitor use in hospitalized patients,” Practical Gastroenterology, vol. 30, no. 5, pp. 24–34, 2006. View at Google Scholar · View at Scopus
  21. C. O'Donoghuea and L. Kyne, “Update on Clostridium difficile infection,” Current Opinion in Gastroenterology, vol. 27, no. 1, pp. 38–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Q. D. Pham, R. E. Regal, T. R. Bostwick, and K. S. Knauf, “Acid suppressive therapy use on an inpatient internal medicine service,” Annals of Pharmacotherapy, vol. 40, no. 7-8, pp. 1261–1266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. A. Zink, M. Pohlman, M. Barnes, and M. E. Cannon, “Long-term use of acid suppression started inappropriately during hospitalization,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 10, pp. 1203–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Nardino, R. J. Vender, and P. N. Herbert, “Overuse of acid suppressive therapy in hospitalized patients,” American Journal of Gastroenterology, vol. 95, no. 11, pp. 3118–3122, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Pasina, A. Nobili, M. Tettamanti et al., “Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly,” European Journal of Internal Medicine, vol. 22, no. 2, pp. 205–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Cunningham, B. Dale, B. Undy, and N. Gaunt, “Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea,” Journal of Hospital Infection, vol. 54, no. 3, pp. 243–245, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Jayatilaka, R. Shakov, R. Eddi, G. Bakaj, W. J. Baddoura, and V. A. DeBari, “Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors,” Annals of Clinical and Laboratory Science, vol. 37, no. 3, pp. 241–247, 2007. View at Google Scholar · View at Scopus